VTAK

Catheter Precision is a $2.1M nano-cap medical-device shell whose numbers describe a company running on fumes. FY2025 revenue of $819K did nearly double YoY (+95%), and reported gross margin is a healthy 92.3%, but the scale is irrelevant next to a -$21.1M operating loss and a -2,581.6% operating margin. Five straight years of deep losses have compounded into a -$310M accumulated deficit. The single most damning line is $88K of cash — down 96.9% YoY — set against -$8.3M of operating cash flow. That is roughly four days of burn on hand, meaning survival is entirely dependent on continuous, near-term capital raises.

The capital structure confirms the distress. Current liabilities ($3.91M, +75.2%) dwarf current assets ($390K, -88.2%), leaving deeply negative working capital, while long-term debt jumped 452% to $3.08M and liabilities/equity sits at 1.31x against shrinking equity of $7.05M. Shares outstanding of 2.69M fell 71% YoY — the signature of a reverse split used to hold a sub-$1 price above delisting thresholds, and reverse splits do nothing to fix the underlying cash hole. Any equity fix from here comes through dilution that, at this valuation, is punishing to holders.